Aflatoxin B1 is an inhibitor of cyclic nucleotide phosphodiesterase activity

General Pharmacology

Volumn 32, Issue 5, 1999, Pages 615-619

  Bonsi, Paola ^a   Augusti Tocco, Gabriella ^a   Palmery, Maura ^a   Giorgi, Mauro ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

Aflatoxin B1; High affinity cyclic nucleotide phosphodiesterase; PDE V isoform

Indexed keywords

AFLATOXIN B1; CYCLIC AMP; CYCLIC GMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; 3',5' CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; ENZYME INHIBITOR; MUTAGENIC AGENT;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BRAIN; CELL LINE; CONTROLLED STUDY; DRUG TOXICITY; ENZYME ACTIVITY; HEART; IN VITRO STUDY; KIDNEY; LIVER; LUNG; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; RAT; SPLEEN; TISSUE SPECIFICITY; ANIMAL; CELL CULTURE; CELL DIVISION; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; MOUSE; WISTAR RAT;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; AFLATOXIN B1; ANIMALS; CELL DIVISION; ENZYME INHIBITORS; FEMALE; MICE; MUTAGENS; RATS; RATS, WISTAR; TUMOR CELLS, CULTURED;

EID: 0032589059     PISSN: 03063623     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-3623(98)00282-1     Document Type: Article

References (22)

1. ++-ATPase. Biosci Reports. 15(4):1995;209-220.
2. Bannasch P., Berrino F., Boorman G.A., Chernozemsky I.N., Dirheimer G., Groopman J.D., Hemminki K., Jongen W.M.F., Knize M., Lu S.H., Marasas W.F.O., Miller A.B., Miller J.D., Nagao M., Neal G.E., Norppa H., Olin S., Olsen J.H., Schulte-Hermann R., Stahlmann R., Tatemtsu M., Venitt S., Visconti A., Wu-Williams A., Zaridze D.G. Some naturally occurring substances. food items and constituents, heterocyclic aromatic amines and mycotoxins IARC Working Group IARC monographs on the evaluation of carcinogenic risks to humans, Vol. 56. 1993;249-395 IARC, Lyon, France.
3. Beavo J.A. Multiple isozymes of cyclic nucleotide phosphodiesterase. Greengard P., Robinson A. Advances in second messenger and phosphoprotein research, Vol. 22. 1988;1-381 Raven Press, New York, NY.
4. Beavo J.A. Multiple phosphodisterase isoenzymes. background, nomenclature and implications Beavo J., Houslay M.D. Cyclic nucleotide phosphodiesterases. structure, regulation and drug action:1990;3-15 John Wiley and Sons, Chichester, New York.
5. Beavo J.A. Cyclic nucleotide phosphodiesterases. functional implication of multiple isoforms Physiol Rev. 75(4):1995;725-748.
6. Busby, W.F., Wogan, G.N., 1984. Aflatoxins. In: Searle, C.E. (Ed)., Chemical carcinogens, ACS Monograph 182. American Chemical Society, Washington, DC, pp. 945-1136.
7. Chao T.C., Maxwell S.M., Wong S.-Y. An outbreak of aflatoxicosis and boric acid poisoning in Malaysia. a clinicopathological study J Pathol. 164:1991;225-233.
8. 1 and acetylaminofluorene to rat, mouse and human hepatocyte DNA. the relationship of DNA binding to carcinogenicity Carcinogenesis. 9(5):1988;711-716.
9. Conti M., Nemoz G., Sette C., Vicini E. Recent progress in understanding the hormonal regulation of phosphodiesterases. Endocrine Rev. 16(3):1995;370-389.
10. Giorgi M., Caniglia C., Scarsella G., Augusti-Tocco G. Characterization of 3′:5′ cyclic nucleotide phosphodiesterase activities of mouse neuroblastoma N18TG2 cells. FEBS Lett. 324(1):1993;76-80.
11. Heathcote J.G., Hibbert J.R. Developments in food science 1. aflatoxins: chemical and biological aspects:1987;Elsevier Science, Amsterdam.
12. Hurwitz R.L., Hansen R.S., Harrison S.A., Martins T.J., Mumby M.C., Beavo J. Immunologic approaches to the study of cyclic nucleotide phosphodiesterases. Strada S.J., Thompson W.J. Advances in cyclic nucleotide and protein phosphorylation research. 1984;80-107 Raven Press, New York.
13. 1 and its association with cellular components in chicken embryo primary cultured cells. Biochim Biophys Acta. 1035:1990;146-153.
14. 1 on the activity of drug-metabolizing enzymes in rat liver. Toxicol Appl Pharmacol. 60:1981;570-578.
15. Kishi Y., Ashikaga T., Numano F. Phosphodiesterases in vascular endothelial cells. Strada S.J., Thompson W.J. Advances in second messenger and phosphoprotein research, Vol. 25. 1992;201-213 Raven Press, New York.
16. Lavan B., Lakey T., Houslay M.D. Resolution of soluble cyclic nucleotide phosphodiesterase isoenzymes, from liver and hepatocytes, identifies a novel IBMX-insensitive form. Biochem Pharmacol. 38:1989;4123-4136.
17. 1 exposure. phosphatidylinositol methabolism Chemico-Biological Interaction. 98:1995;145-152.
18. Nicholson C.D., Chaliss R.A.J., Shahid M. Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes. Trends Pharmacol Sci. 12:1991;19-27.
19. Palmery M., Abdel-Haq A., Luzi A., Bonsi P., Leone M.G. Effetti della somministrazione acuta di aflatossine sul tratto gastrointestinale (Abstract) II Congr. 1995;Cell-Tox, Ivrea, Italy.
20. Thompson W.J., Appleman M.M. Multiple cyclic nucleotide phosphodiesterase activities from rat brain. Biochem. 10:1971;311-316.
21. 1 on human platelet protein Kinase C. Int J Biochem. 23(9):1991;839-843.
22. 1 alters protein phosphorylation in rat livers. Biochem Biophys Res Comm. 129(2):1985;342-349.